Do you want to read an article? Please log in or register.
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors
Rheumatoid Arthritis
Related content
Rheumatoid Arthritis
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Ann Rheum Dis.
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JM, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D
doi: 10.1136/annrheumdis-
Rheumatoid Arthritis
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
Ann Rheum Dis.
Kerschbaumer A, Sepriano A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JWJ, Burmester GR, de Wit M, Falzon L, Landewé R
doi: 10.1136/annrheumdis-2019-216656.
Rheumatoid Arthritis
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial
JAMA.
Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Lioté F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P
doi: 10.1001/jama.2016.13512.
Rheumatoid Arthritis
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
Arthritis Rheumatol.
Charles-Schoeman C, DeMasi R, Valdez H, Soma K, Hwang LJ, Boy MG, Biswas P, McInnes IB
doi: 10.1002/art.40911.
COMMENTED
Rheumatoid Arthritis
Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)
★ 2
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1136/annrheumdis-2019-216819.
Rheumatoid Arthritis
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
Clin Rheumatol.
van der Heijde D, Durez P, Schett G, Naredo E, Østergaard M, Meszaros G, De Leonardis F, de la Torre I, López-Romero P, Schlichting D, Nantz E, Fleischmann R
doi: 10.1007/s10067-018-4221-0.
Autoimmune DiseaseRheumatoid Arthritis
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis
BioDrugs.
Nakayamada S, Kubo S, Iwata S, Tanaka Y
doi: 10.1007/s40259-016-0190-5
COMMENTED
Rheumatoid Arthritis
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1186/s13075-019-2059-8.
Rheumatoid Arthritis
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
Rheumatol Ther.
Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V
doi: 10.1007/s40744-017-0077-z.